Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04959903 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT
A Phase 1 study of Hematological Malignancies, sponsored by Smart Immune SAS.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT04959903: Recruiting Phase 1 study of Hematological Malignancies, sponsored by Smart Immune SAS.
NCT04959903 is a Phase 1 study of Hematological Malignancies that is actively recruiting participants, run by Smart Immune SAS. The registered enrollment target is 36 participants, below the 774-participant average among 16 other Hematological Malignancies trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04959903, a Phase 1 study of Hematological Malignancies, is actively recruiting participants, sponsored by Smart Immune SAS.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the safety and the efficacy of SMART101 (Human T Lymphoid Progenitor (HTLP)) injection to accelerate immune reconstitution after T cell depleted allogeneic hematopoietic stem cell transplantation (HSCT) in adult and pediatric patients with hematological malignancies.
Primary Outcome
to evaluate the safety profile of the study drug
Conditions Studied
Interventions
- BIOLOGICAL Allogeneic T cell progenitors, cultured ex-vivo
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center (MSKCC) - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2022-03-31 |
| Est. Completion | 2027-05 |
| Phase | Phase 1 |
What NCT04959903 shows while recruiting
NCT04959903 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 774-participant average among 16 other Hematological Malignancies trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Hematological Malignancies appearing as the primary indexed condition, and to 1 intervention - of which Allogeneic T cell progenitors, cultured ex-vivo is the first listed.
NCT04959903 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04959903 about?
NCT04959903 is a clinical study titled "Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT". The purpose of this study is to evaluate the safety and the efficacy of SMART101 (Human T Lymphoid Progenitor (HTLP)) injection to accelerate immune reconstitution after T cell depleted allogeneic hematopoietic stem cell transplantation (HSCT) in adult and pediatric patients with hematological malig...
What is the current status of trial NCT04959903?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2022-03-31. Estimated completion is 2027-05.
What conditions does trial NCT04959903 study?
This clinical trial studies the following conditions: Hematological Malignancies.
What interventions are being tested in trial NCT04959903?
The interventions under investigation include: Allogeneic T cell progenitors, cultured ex-vivo (BIOLOGICAL).
Who is sponsoring clinical trial NCT04959903?
This trial is sponsored by Smart Immune SAS, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04959903 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematological Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04959903's enrollment target sits among peer trials
36 13th of 16 higher than 2 of 16 other Hematological Malignancies trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hematological Malignancies trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
RECRUITING · Phase 1
-
Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 1
-
Durvalumab and Tremelimumab for Pediatric Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 1
-
Study of AZD9829 in CD123+ Hematological Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI